TB & Malaria Drug Reengineering: A New Hope
Here’s a breakdown of the provided text, focusing on the key information about fosmidomycin and Cynthia Dowd’s research:
Main Topic: Research into improving the antibiotic fosmidomycin to combat drug-resistant tuberculosis (TB) and malaria.
Key Points:
Fosmidomycin’s Mechanism: It targets the methylerythritol phosphate (MEP) pathway, essential for several disease-causing organisms but absent in humans.This makes it a promising drug candidate.
Cynthia Dowd’s Work: A chemist at George Washington university, Dowd has been working for over a decade to engineer fosmidomycin analogs to be more effective. Presentation at ACS meeting: Dowd presented her lab’s progress at the American Chemical Society Fall 2025 meeting, showing that some variants are more potent against TB and malaria.
Target Enzyme: Fosmidomycin disrupts the MEP pathway by inhibiting 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr). Limitations of Current Fosmidomycin: While it works, its “pharmacokinetic properties stink” (meaning it doesn’t get to the target effectively).
Prodrug Approach: Dowd’s team is using a prodrug strategy to improve fosmidomycin’s effectiveness, notably for TB, which has a tough cell wall. They are adding lipophilic (greasy) phosphonate esters to help the drug penetrate the cell wall.
* Goal: To overcome growing drug resistance in TB and malaria by creating a more effective drug that targets a unique pathway.In essence,the article highlights a promising avenue for developing new antibiotics by modifying an existing compound (fosmidomycin) to overcome its limitations and target essential pathways in disease-causing organisms.